Wu, Junying
Zhang, Yudi
Qin, Tiejun
Xu, Zefeng
Qu, Shiqiang
Pan, Lijuan
Li, Bing
Jia, Yujiao
Li, Chengwen
Wang, Huijun
Gao, Qingyan
Cai, Wenyu
Gong, Jingye
Zhao, Songyang
Li, Fuhui
Gale, Robert Peter
Xiao, Zhijian
Funding for this research was provided by:
National Institute of Health Research (NIHR) Biomedical Research Centre and the Ministry of Science and Technology of China (84000-51200002)
National Natural Science Fund (Nos. 81530008 and 81870104)
CAMS Initiative Fund for Medical Sciences (Nos. 2016-I2M-1-001 and 2020-I2M-C&T-A-020 and 2020-I2M-C&T-B-090)
Haihe Laboratory of Cell Ecosystem Innovation Fund (HH22KYZX0033)
Article History
Received: 8 September 2022
Accepted: 29 September 2022
First Online: 17 October 2022
Declarations
:
: The study was approved by the Ethical Committee on Medical Research at Institute of Hematology and Blood Disease Hospital.
: Oral or written informed consent was obtained for each patient.
: RPG is a consultant to NexImmune Inc. Nanexa Pharma, Ascentage Pharm Group and Antengene Biotech LLC, Medical Director of FFF Enterprises Inc.; Partner in AZAC Inc.; Board of Directors of Russian Foundation for Cancer Research Support and Scientific Advisory Board: StemRad Ltd.